Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPXNASDAQ:DBVTNASDAQ:HRTXNASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$2.09-0.5%$1.91$0.77▼$4.08$289.01M1.4920,626 shs529,883 shsDBVTDBV Technologies$8.41-4.1%$8.03$2.20▼$12.78$230.35M-0.66189,969 shs61,648 shsHRTXHeron Therapeutics$1.85-1.1%$2.09$1.04▼$3.93$282.24M1.332.28 million shs780,850 shsIMABI-Mab$0.99-5.7%$0.84$0.60▼$2.00$80.69M1.13307,506 shs184,463 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics-0.48%-0.48%+0.97%-28.42%+33.97%DBVTDBV Technologies-4.10%-24.23%-9.18%+91.57%+36.11%HRTXHeron Therapeutics-1.07%-6.09%-16.10%+6.94%-46.69%IMABI-Mab-5.71%+10.00%+16.68%+1.33%-43.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMPXCompass Therapeutics3.8776 of 5 stars4.63.00.00.03.05.00.0DBVTDBV Technologies2.8173 of 5 stars3.54.00.00.02.71.70.6HRTXHeron Therapeutics3.7996 of 5 stars3.50.00.04.24.11.70.6IMABI-Mab2.963 of 5 stars3.75.00.00.01.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 3.11Buy$13.13527.99% UpsideDBVTDBV Technologies 3.00Buy$15.5084.30% UpsideHRTXHeron Therapeutics 3.00Buy$5.50197.30% UpsideIMABI-Mab 3.33Buy$5.50455.56% UpsideCurrent Analyst Ratings BreakdownLatest IMAB, DBVT, HRTX, and CMPX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.005/1/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $15.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.004/4/2025IMABI-MabHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $7.004/4/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K340.01N/AN/A$1.17 per share1.79DBVTDBV Technologies$15.73M14.64N/AN/A$7.27 per share1.16HRTXHeron Therapeutics$148.52M1.90N/AN/A($0.23) per share-8.04IMABI-Mab$3.27M24.65N/AN/A$2.93 per share0.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)DBVTDBV Technologies-$72.73M-$4.92N/AN/AN/A-815.73%-106.07%-76.17%7/29/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)IMABI-Mab-$206.44MN/A0.00N/AN/AN/AN/AN/AN/ALatest IMAB, DBVT, HRTX, and CMPX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million4/11/2025Q4 2024DBVTDBV TechnologiesN/A-$1.10N/A-$1.10N/A$0.51 million2/27/2025Q4 2024CMPXCompass Therapeutics-$0.10-$0.11-$0.01-$0.11N/AN/A2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A31.8431.84DBVTDBV TechnologiesN/A2.222.22HRTXHeron TherapeuticsN/A2.281.74IMABI-MabN/A15.9915.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%DBVTDBV Technologies71.74%HRTXHeron Therapeutics80.01%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics29.80%DBVTDBV Technologies1.90%HRTXHeron Therapeutics5.86%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20138.28 million98.38 millionNot OptionableDBVTDBV Technologies8027.39 million20.18 millionOptionableHRTXHeron Therapeutics300152.56 million143.33 millionOptionableIMABI-Mab38081.50 million63.49 millionOptionableIMAB, DBVT, HRTX, and CMPX HeadlinesRecent News About These CompaniesI-Mab to Present at Jefferies Global Healthcare Conference and Share New Givastomig Data at ESMO GI Cancers Congress 2025May 21 at 3:41 PM | nasdaq.comI-Mab to Present at Jefferies Global Healthcare ConferenceMay 20, 2025 | globenewswire.comI-Mab Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 17, 2025 | taiwannews.com.twI-Mab’s Financial Report Highlights Givastomig ProgressMay 17, 2025 | tipranks.comI-Mab’s Promising Clinical Developments and Financial Stability Earn ‘Buy’ Rating from AnalystMay 15, 2025 | tipranks.comI-Mab (NASDAQ:IMAB) Shares Sold by Hhlr Advisors LTD.May 1, 2025 | marketbeat.comI-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025April 30, 2025 | gurufocus.comAfter Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)April 14, 2025 | zacks.comAfter Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)April 11, 2025 | zacks.comI-Mab’s Transformative Year: Financial and Strategic HighlightsApril 5, 2025 | tipranks.comI-Mab price target lowered to $7 from $8 at H.C. WainwrightApril 4, 2025 | markets.businessinsider.comI-Mab Positions for Growth with U.S. Focus and Innovative Cancer TreatmentsApril 4, 2025 | tipranks.comPromising Pipeline and Strong Financial Position Drive Buy Rating for I-MabApril 4, 2025 | tipranks.comI-Mab Reports Full Year 2024 Financial Results and Provides Business UpdateApril 3, 2025 | gurufocus.comI-Mab stock touches 52-week low at $0.72 amid market challengesApril 3, 2025 | investing.comI-Mab to Present at 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | markets.businessinsider.comI-Mab faces Nasdaq delisting over bid price ruleMarch 23, 2025 | investing.comI-Mab receives Nasdaq deficiency noticeMarch 22, 2025 | markets.businessinsider.comI-Mab Receives Nasdaq Deficiency Notice for Minimum Bid PriceMarch 21, 2025 | tipranks.comI-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price RequirementMarch 21, 2025 | globenewswire.comI-Mab Biopharma: I-Mab Announces Accelerated Givastomig Phase 1b Study ProgressMarch 7, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMAB, DBVT, HRTX, and CMPX Company DescriptionsCompass Therapeutics NASDAQ:CMPX$2.09 -0.01 (-0.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.18 +0.10 (+4.55%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.DBV Technologies NASDAQ:DBVT$8.47 -0.30 (-3.42%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.Heron Therapeutics NASDAQ:HRTX$1.85 -0.02 (-1.07%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.83 -0.02 (-1.08%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.I-Mab NASDAQ:IMAB$0.99 -0.06 (-5.71%) Closing price 05/23/2025 03:58 PM EasternExtended Trading$0.97 -0.02 (-2.02%) As of 05/23/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
